Holst, Jens J.

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 3,371

Type 2 diabetes mellitus

DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 2,611

Glucagon-like peptide 1 (GLP-1)

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 1,868

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 1,651

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 1,402

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 1,297

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 1,092

Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition

Kootte, R. S., Levin, E., Salojärvi, J., Smits, L. P., Hartstra, A. V., Udayappan, S. D., Hermes, G., Bouter, K. E., Koopen, A. M., Holst, J. J., et al. (2017) · Cell Metabolism

Gut microbiota and healthGastrointestinal motility and disorders

Cited by 1,039

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations

Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine

Pancreatic function and diabetesIon channel regulation and function

Cited by 988

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine

Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

Cited by 963

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 869

Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus

Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 868

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 792

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism

Diabetes Treatment and ManagementNitric Oxide and Endothelin Effects

Cited by 680

Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man

Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences

Diabetes Treatment and ManagementNeuropeptides and Animal Physiology

Cited by 670

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem

Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience

Regulation of Appetite and ObesityNeuropeptides and Animal Physiology

Cited by 663

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 611

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 605

Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism

Patti, M., Houten, S. M., Bianco, A. C., Bernier, R., Larsen, P. R., Holst, J. J., Badman, M. K., Maratos‐Flier, E., Mun, E. C., Pihlajamaki, J., et al. (2009) · Obesity

Bariatric Surgery and OutcomesGut microbiota and health

Cited by 591

The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion

Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 582

Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice

Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 563

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight

Diabetes Treatment and ManagementReceptor Mechanisms and Signaling

Cited by 541

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 536

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 528